Linked Life Data

7137035

Source:http://linkedlifedata.com/resource/pubmed/id/7137035

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1982-12-18
pubmed:abstractText
Like ajmaline, procainamide can be used to identify patients with the Wolff-Parkinson-White syndrome who have a short refractory period of the accessory pathway in an anterograde direction. Procainamide given intravenously in a maximal dose of 10 mg/kg body weight over a 5 minute period during sinus rhythm produced complete anterograde block in the accessory pathway in 20 of 39 patients. An electrophysiologic investigation performed 24 to 48 hours later revealed that in 19 of the 20 patients the effective refractory period of the accessory pathway was 270 ms or greater. In 18 of the 19 patients not exhibiting anterograde block in the accessory pathway, the refractory period was less than 270 ms. When ajmaline was compared with procainamide in the same patients, 100 mg of procainamide had approximately the same effect as 10 mg of ajmaline. The use of intravenous procainamide is a reliable and rapid method of identifying patients with the Wolff-Parkinson-White syndrome who may be at risk for circulatory insufficiency or sudden death in case of atrial fibrillation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1087-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway.
pubmed:publicationType
Journal Article, Comparative Study